Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Newton

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
Critical Reviews in Oncology/Hematology|May 16, 2018
Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular systemHani M Babiker, Ali McBride, Michael Newton, et al.
Lung Cancer (Amsterdam, Netherlands)|March 4, 2022
Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trialJarushka Naidoo, Johan F Vansteenkiste, Corinne Faivre-Finn, et al.
Future Oncology (London, England)|July 18, 2024
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancerFabrice Barlesi, Byoung Chul Cho, Sarah B Goldberg, et al.
American Journal of Obstetrics and Gynecology|February 21, 2022
In vivo Raman spectroscopy monitors cervical change during laborLaura E Masson, Christine M O'Brien, Rekha Gautam, et al.
Clinical Lung Cancer|July 23, 2021
Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC)Mark A Socinski, Mustafa Özgüroğlu, Augusto Villegas, et al.
Journal of Neurosurgery. Pediatrics|March 28, 2025
Does interfacility transfer affect outcomes in myelomeningocele repair? A National Surgical Quality Improvement Program Pediatric analysisSara C Chaker, Andrew J James, Lauren E Sullivan, et al.
Annals of Plastic Surgery|May 20, 2026
In-Utero Myelomeningocele Repair: Historical Evolution, Technical Refinements, and Global Impact of the Vanderbilt ExperienceBarite Gutama, Ricardo A Torres-Guzman, Sahar Borna, et al.
JTO Clinical and Research Reports|March 8, 2024
Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLCJohan F Vansteenkiste, Jarushka Naidoo, Corinne Faivre-Finn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2026
Erratum: Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 StudyJeffrey D Bradley, Shunichi Sugawara, Ki Hyeong Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2025
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 StudyJeffrey D Bradley, Shunichi Sugawara, Ki Hyeong Lee, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
Critical Reviews in Oncology/Hematology|May 16, 2018
Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular systemHani M Babiker, Ali McBride, Michael Newton, et al.
Lung Cancer (Amsterdam, Netherlands)|March 4, 2022
Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trialJarushka Naidoo, Johan F Vansteenkiste, Corinne Faivre-Finn, et al.
Future Oncology (London, England)|July 18, 2024
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancerFabrice Barlesi, Byoung Chul Cho, Sarah B Goldberg, et al.
American Journal of Obstetrics and Gynecology|February 21, 2022
In vivo Raman spectroscopy monitors cervical change during laborLaura E Masson, Christine M O'Brien, Rekha Gautam, et al.
Clinical Lung Cancer|July 23, 2021
Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC)Mark A Socinski, Mustafa Özgüroğlu, Augusto Villegas, et al.
Journal of Neurosurgery. Pediatrics|March 28, 2025
Does interfacility transfer affect outcomes in myelomeningocele repair? A National Surgical Quality Improvement Program Pediatric analysisSara C Chaker, Andrew J James, Lauren E Sullivan, et al.
Annals of Plastic Surgery|May 20, 2026
In-Utero Myelomeningocele Repair: Historical Evolution, Technical Refinements, and Global Impact of the Vanderbilt ExperienceBarite Gutama, Ricardo A Torres-Guzman, Sahar Borna, et al.
JTO Clinical and Research Reports|March 8, 2024
Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLCJohan F Vansteenkiste, Jarushka Naidoo, Corinne Faivre-Finn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2026
Erratum: Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 StudyJeffrey D Bradley, Shunichi Sugawara, Ki Hyeong Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2025
Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 StudyJeffrey D Bradley, Shunichi Sugawara, Ki Hyeong Lee, et al.
Pageof 9